InnoCare Pharma Balance Sheet Health
Financial Health criteria checks 5/6
InnoCare Pharma has a total shareholder equity of CN¥6.9B and total debt of CN¥1.6B, which brings its debt-to-equity ratio to 23.2%. Its total assets and total liabilities are CN¥9.7B and CN¥2.7B respectively.
Key information
23.2%
Debt to equity ratio
CN¥1.61b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥7.30b |
| Equity | CN¥6.94b |
| Total liabilities | CN¥2.74b |
| Total assets | CN¥9.68b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9969's short term assets (CN¥8.1B) exceed its short term liabilities (CN¥2.1B).
Long Term Liabilities: 9969's short term assets (CN¥8.1B) exceed its long term liabilities (CN¥637.4M).
Debt to Equity History and Analysis
Debt Level: 9969 has more cash than its total debt.
Reducing Debt: 9969 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9969 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 9969 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.